J&J strengthens biotech business
October 24, 2003Janssen, Janssen Cilag, Johnson & Johnson, Scios
Johnson & Johnson is to expand its biotech capabilities with a $2.4 billion purchase of US company Scios.The deal, still …
vCJD caution prompts Serono product withdrawal
October 24, 2003Serono is to withdraw one of its hormone products from the UK after a case of variant Creutzfeldt-Jakob disease was …
Iressa filed in Europe amid safety concerns
October 24, 2003AstraZeneca has submitted its lung cancer drug Iressa for approval in Europe, despite concerns about side-effects.The novel drug was launched …
New trial for treatment-resistant HIV
October 24, 2003Boehringer Ingelheim has begun a global phase III trial for a new drug it hopes will be effective for HIV …
Former ImClone chief fined $800,000 for insider dealing
October 24, 2003Former ImClone boss Samuel Waksal has agreed to pay $800,000 to settle some of the charges brought against him by …
GSK puts new slant on Garnier pay battle
October 24, 2003GlaxoSmithKline is to raise the issue of Chief Executive Jean-Pierre Garnier's pay once again this week, saying it is intended …
EU to conclude Pfizer-Pharmacia review in coming weeks
October 24, 2003The European Commission has restarted its review of Pfizer's merger with Pharmacia, and now expects to complete the investigation of …
Conflict of interests halt Seroxat inquiry
October 24, 2003If you were to ask leading CRO executives they would tell you that blue chip pharma companies outsource their critical …
AstraZeneca files first for European bipolar disorder
October 24, 2003AstraZeneca have filed the first European marketing application for an atypical antipsychotic as a treatment for manic episodes related to …
Lilly’s well-planned campaign launches ‘spontaneity’ ED drug
October 24, 2003Eli Lilly have launched Cialis, the first serious rival to blockbuster erectile dysfunction drug Viagra amid a flurry of media …
Aventis cautious as growth slows
October 24, 2003Aventis has reined in its 2003 forecasts and warned investors that the pace of its growth would slow to a …
Elan shows $2.4bn loss for 2002
October 24, 2003Irish pharmaceutical company Elan made a larger than expected loss of $2.39 billion last year.Shares in the troubled company fell …
Pfizer rivals face uphill struggle
October 24, 2003Pharmaceutical companies attempting to keep up with Pfizer's industry lead have a battle on their hands, according to analysts Datamonitor.New …
Why can’t pharma be more like this?
October 24, 2003Research and Development, Sales and Marketing branding, corporate
Brands are compressed bytes of information. They contain myriad messages that create impressions. If these impressions net out in a …
Industry concern over EU reform
October 24, 2003A serious lack of progress in EU moves to reform pharmaceutical regulation is now jeopardising key objectives, according to European …
FDA to streamline approval process
October 24, 2003The FDA has launched a programme to speed up approval of new drugs in response to growing concerns about lengthening …
GSK productivity picking up
October 24, 2003GlaxoSmithKline's early-stage pipeline of new drugs has shown big improvements recently, according to analysts Deutsche Bank."These metrics could be taken …
R&D outsourcing strategies
October 24, 2003Research and Development CRO, contract research, contract research organisation
The R&D and sales and marketing functions of major pharma companies are suffering from declining productivity. To date, the industry's …
